AstraZeneca reports total sales of $12,679 million for the 1st quarter, up 17% on the same period a year earlier (or +19% at constant exchange rates).

Pre-tax earnings came to $2,800 million, up 24% (+34% at constant exchange rates).

The Anglo-Swedish laboratory reported adjusted quarterly EPS of $1.41, up 21% (+30% at constant exchange rates) on Q1 2023.
Core EPS came to $2.06, up 7% (+13% at constant exchange rates).

Pascal Soriot, CEO of AstraZeneca, also highlighted the positive and "unprecedented" trial results obtained for Imfinzi and Tagrisso in lung cancer.

"We also look forward to seeing the results of several other important trial projects throughout the year", he added.

Against this backdrop, AstraZeneca will announce a 7% increase in the annual dividend at its Annual General Meeting.

For 2024, AstraZeneca confirms its targets, with total sales and core EPS expected to rise by around 10% to 14%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.